CAS: 866460-33-5 - Setipiprant
Fórmula:C24H19FN2O3
InChI:InChI=1S/C24H19FN2O3/c25-16-8-9-21-19(12-16)20-13-26(11-10-22(20)27(21)14-23(28)29)24(30)18-7-3-5-15-4-1-2-6-17(15)18/h1-9,12H,10-11,13-14H2,(H,28,29)
Clave InChI:InChIKey=IHAXLPDVOWLUOS-UHFFFAOYSA-N
SMILES:O=C(O)CN1C=2C=CC(F)=CC2C3=C1CCN(C(=O)C4=CC=CC=5C=CC=CC54)C3
| Marca | Datos del producto | Pureza | Rango de precios | Entrega estimada |
|---|---|---|---|---|
 | 2-(2-(1-naphthoyl)-8-fluoro-1,2,3,4-tetrahydropyrido[4,3-b]indol-5-yl)acetic acid REF: IN-DA00GU6HCAS: 866460-33-5 | 98% | A consultar | Mar 10 Dic 24 |
 | Setipiprant REF: TM-T3520CAS: 866460-33-5 | 99.16% | 35,00 €~260,00 € | Mar 17 Dic 24 |
 | Setipiprant(ACT-129968) REF: 3D-RJB46033CAS: 866460-33-5 | Min. 95% | A consultar | Mar 21 Ene 25 |
![2-(2-(1-naphthoyl)-8-fluoro-1,2,3,4-tetrahydropyrido[4,3-b]indol-5-yl)acetic acid](https://static.cymitquimica.com/products/IN/thumb/DA00GU6H.jpg)
2-(2-(1-naphthoyl)-8-fluoro-1,2,3,4-tetrahydropyrido[4,3-b]indol-5-yl)acetic acid
CAS:866460-33-5
Fórmula:
C24H19FN2O3
Pureza:
98%
Forma y color:
Solid
Peso molecular:
402.4177
Ref: IN-DA00GU6H
| 5mg | 87,00 € | ||
| 25mg | 187,00 € | ||
| 100mg | 545,00 € | ||
| 250mg | A consultar |
Entrega estimada en Estados Unidos, el Martes 10 de Diciembre de 2024
Setipiprant
CAS:866460-33-5
Setipiprant (ACT-129968) is an oral CRTH2 antagonist for asthma/allergy, targeting PGD2-induced inflammation (IC50: 6.0 nM).
Fórmula:
C24H19FN2O3
Pureza:
99.16%
Forma y color:
Solid
Peso molecular:
402.42
Ref: TM-T3520
| 10mg | 46,00 € | ||
| 25mg | 78,00 € | ||
| 50mg | 114,00 € | ||
| 100mg | 176,00 € | ||
| 200mg | 260,00 € | ||
| 1mL*10mM (DMSO) | 36,00 € |
Entrega estimada en Estados Unidos, el Martes 17 de Diciembre de 2024
Setipiprant(ACT-129968)
CAS:866460-33-5
Setipiprant is a CRTH2-selective antagonist, which has been shown to be effective in reducing the …
Fórmula:
C24H19FN2O3
Pureza:
Min. 95%
Peso molecular:
402.42 g/mol
Ref: 3D-RJB46033
| 100mg | A consultar |
Entrega estimada en Estados Unidos, el Martes 21 de Enero de 2025
